Diabetes Treatment Raises Cholesterol Ratio

JULY 01, 2003

A new study has found that the type 2 diabetes treatment rosiglitazone increased high-density lipoprotein (HDL, or "good") cholesterol levels and improved the ratio of total cholesterol to HDL cholesterol in patients with type 2 diabetes. Data from the study were presented recently at the Annual Scientific Session of the American College of Cardiology.

In the study?which analyzed the results of open-label extensions of 2 placebo-controlled, double-blind studies?a total of 269 patients were given 8 mg of rosiglitazone daily for 24 months. In all the patients, mean HDL cholesterol levels increased by 15%, with increases of 25% in patients with HDL cholesterol levels <40 mg/dL at baseline.The ratio of cholesterol to HDL cholesterol improved for all the patients, with an overall decrease from 5.06 to 4.7 over 2 years. In patients with a ratio >5, the mean ratio decreased from 6.25 to 5.6.



SHARE THIS SHARE THIS
0

Conference Coverage

Check back here regularly for live conference coverage from the American Academy of Pain Medicine and the upcoming American Pharmacists Association Meeting and Expo. 


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.